ERBB2 and breast carcinoma: These observations suggest that more aggressive basal-like breast cancers have the capacity to be stimulated by autocrine EGFR signaling, whereas the ligands produced by other subtypes of breast cancer (luminal, HER2 positive) may serve as paracrine signaling molecules [13].